Research programme: myelosuppression therapy - Biothera

Drug Profile

Research programme: myelosuppression therapy - Biothera

Alternative Names: Imprime WGP

Latest Information Update: 18 Sep 2006

Price : $50

At a glance

  • Originator Biothera
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Myelosuppression

Most Recent Events

  • 18 Sep 2006 Biothera has been awarded a SBIR grant for the treatment of acute radiation exposure with Imprime WGP™
  • 25 Oct 2005 Preclinical trials in Myelosuppression in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top